COMP <GO>
CGEM vs GLUE // FORWARD P/E MULTIPLE
Cullinan Therapeutics Inc. (NASDAQ) VS. Monte Rosa Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CGEM 2
— GLUE 2
■ METRIC PARITY
LAST: $15.03 (-2.72%) • MKT CAP: $994.3M
forward-pe
—
LAST: $10.76 (-1.01%) • MKT CAP: $927.4M
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGEM VS. GLUE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CGEM | GLUE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -17.68% | -2.97% | -14.71 | GLUE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | GLUE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 46.2 | +2.50 | CGEM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $994.3M | $927.4M | $66.9M | CGEM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CGEM REV | GLUE REV | CGEM GROSS % | GLUE GROSS % | CGEM FCF | GLUE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$175.8M | -$27.5M |
| FY 2024 | $0 | $0 | — | — | -$145.3M | $38.0M |
| FY 2023 | $0 | $0 | — | — | -$134.3M | -$43.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGEM // BETA —
GLUE // BETA —